Novartis voluntarily pulled back its planned price increases, saying it wants the costs of its medications to be “reasonable.”
“We thought the prudent thing to do was to pull back on any further price increases in 2018 and evaluate as the environment evolves,” Novartis CEO Vas Narasimhan told Bloomberg.
Novartis is the latest drugmaker to roll back planned price increases as pharmaceutical companies face increased pressure to lower drug prices.
Pfizer increased the prices of about 100 drugs and treatments July 1. However, it decided to delay some drug price increases after President Trump tweeted that the company should be “ashamed” of the move.
More articles on pharmacy:
Packaging concerns force Novartis, Sandoz to recall 12 drugs
Pfizer stock value dips after Trump’s tweet
8 lesser-known facts about Pfizer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.